Description: Vicore Pharma Holding AB (publ) engages in the research and development of pharmaceutical products for the treatments for rare lung diseases. The company is developing VP01, a small molecule compound for oral administration that is in phase II clinical trial for the treatment of interstitial lung diseases, idiopathic pulmonary fibrosis (IPF), systemic sclerosis, and COVID-19; and VP02, a formulation and delivery route for an existing immunomodulatory compound, which is preclinical trials to treat patients with IPF. It has a cooperation and development agreement with Emeriti Bio AB; license agreement with Nanologica AB (publ); and a collaboration agreement with Alex Therapeutics AB for the development and clinical validation of a digital therapeutic (DTx) built on the Alex DTx platform. The company was formerly known as Mintage Scientific AB. Vicore Pharma Holding AB (publ) was founded in 2000 and is headquartered in Gothenburg, Sweden.
Home Page: www.vicorepharma.com
Kronhusgatan 11
Gothenburg,
411 05
Sweden
Phone:
46 3 17 88 05 60
Officers
| Name | Title |
|---|---|
| Dr. Carl-Johan Dalsgaard M.D., Ph.D. | Chief Exec. Officer |
| Mr. Hans Jeppsson Ph.D. | Chief Financial Officer |
| Dr. Johan Raud Ph.D. | Chief Scientific Officer |
| Ms. Nina Carlen | Chief Admin. Officer |
| Ms. Johanna Grans Ph.D. | Head of Preclinical Devel. |
| Dr. Kicki Johansson | Chief Clinical Devel. Officer |
| Dr. Rohit Batta | Chief Medical Officer |
| Ms. Elin Rosendahl | VP Clinical Devel. |
| Ms. Jessica Shull | Head of Digital Therapeutics |
| Ms. Asa Magnusson | Chief Commercial Officer |
Exchange: ST
Country: SE : Sweden
Currency: Swedish krone (kr)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 8.6737 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 23 |